He Neuraxpharm pharmaceutical group, specialized in the treatment of the Central Nervous System (CNS), launches Duoxone (oxycodone/naloxone) EFG with an innovative prolonged-release technology that allows the tablet to be broken.
He Chronic pain is considered a public health problem worldwide., being the most frequent cause of suffering and disability with a significant impact on people’s quality of life. It negatively affects bodily functions, causing and intensifying sleep disorders, decreased appetite, limiting exercise and physical activity capabilities, and social relationships.
Duoxone are EFG prolonged-release tablets indicated for the treatment of severe pain in adults
According to a study conducted by NHWS, in Spain 6.1 million people suffer from chronic pain, which is equivalent to 17% of the population. The results of the study also highlight a higher prevalence of pain in women (61% vs 39%). On the other hand, the conclusions underline that 46.4% have daily pain, being 81% intense in character. Finally, another of the aspects highlighted in the study is that 80% of people with severe pain have prescribed treatment, while 20% either do not take treatment or do so using freely dispensed drugs.
In this context, EFG prolonged-release tablets are indicated for the treatment of severe pain in adults that can only be adequately treated with opioid analgesics. In this case, the opioid antagonist naloxone has been added to counter constipation by blocking the action of oxycodone on opioid receptors found in the intestine. It is presented in 5mg/2.5mg, 10mg/5mg, 20mg/10mg, 30mg/15mg and 40mg/20mg formats, and all the tablets can be divided, with the exception of Duoxone 5mg/2.5mg, presentation designed to facilitate titration at the start of treatment and to adjust the dose.
The launch of this drug expands the possibilities in the approach of intense pain, through its new presentation of 30mg/15mg and the innovative prolonged-release technology that allows the tablet to be broken. Before starting treatment with opioid analgesics, offer the patient exhaustive information about its use to put to good use.